Relugolix launch date

Relugolixon202012month22 Repagliflozinis a non-peptide small moleculeGnRH receptor antagonist. The chemical name is N-（4-{ 1-[(2,6-Difluorophenyl)methyl]-5-[(Dimethylamino)methyl]-3- (6-methoxypyridazine-3-yl)-2, 4-dioxo -1, 2, 3, 4-tetrahydrothieno[2, 3-d]pyrimidine-6-yl}phenyl)-N’-methoxyurea.

Relugolix(Relugolix)is a white to off-white to slightly yellow solid, with a solubility in25℃water of 0.04mg per milliliter. Relugolix(Relugolix)is available as film-coated tablets for oral administration. Each tablet contains120mg of riluglide. The inactive ingredients are mannitol, sodium starch glycolate, hydroxypropylcellulose, magnesium stearate, hypromellose, titanium dioxide, iron oxide red, and carnauba wax.

Repagolicis a non-peptideGnRHReceptor antagonists competitively bind to pituitary GnRH receptors, thereby reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby reducing the release of testosterone. The most common adverse reactions (≥10%) among patients treated with Repagliflox were hot flashes, musculoskeletal pain, fatigue, diarrhea, and constipation. The most common laboratory abnormalities (≥15%) are elevated glucose, triglycerides, alanine aminotransferase, and aspartate aminotransferase. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.